Back to Search
Start Over
Hurdles to breakthrough in CAR T cell therapy of solid tumors.
- Source :
- Stem Cell Research & Therapy; 4/1/2022, Vol. 13 Issue 1, p1-19, 19p
- Publication Year :
- 2022
-
Abstract
- Autologous T cells genetically engineered to express chimeric antigen receptor (CAR) have shown promising outcomes and emerged as a new curative option for hematological malignancy, especially malignant neoplasm of B cells. Notably, when T cells are transduced with CAR constructs, composed of the antigen recognition domain of monoclonal antibodies, they retain their cytotoxic properties in a major histocompatibility complex (MHC)-independent manner. Despite its beneficial effect, the current CAR T cell therapy approach faces myriad challenges in solid tumors, including immunosuppressive tumor microenvironment (TME), tumor antigen heterogeneity, stromal impediment, and tumor accessibility, as well as tribulations such as on-target/off-tumor toxicity and cytokine release syndrome (CRS). Herein, we highlight the complications that hamper the effectiveness of CAR T cells in solid tumors and the strategies that have been recommended to overcome these hurdles and improve infused T cell performance. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17576512
- Volume :
- 13
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Stem Cell Research & Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 156108394
- Full Text :
- https://doi.org/10.1186/s13287-022-02819-x